Mallinckrodt acquires controversial MS drug developer

Only a few weeks after completing the US$1.4bn acquisition of Cadence Pharmaceuticals, the Irish American pharmaceutical company Mallinckrodt has announced a more ambitious deal, with the US$5.6bn purchase of the…